Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy

Gezer,Ugur; Keskin,Serkan; İğci,Abdullah; Tükenmez,Mustafa; Tiryakioğlu,Duygu; Çetinkaya,Merve; Dişci,Rian; Dalay,Nejat; Eralp,Yeşim

doi:10.3892/ol.2014.2188

August-2014 Volume 8 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2014 Volume 8 Issue 2

Full Size Image

Article

Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy

Authors:
- Ugur Gezer
- Serkan Keskin
- Abdullah İğci
- Mustafa Tükenmez
- Duygu Tiryakioğlu
- Merve Çetinkaya
- Rian Dişci
- Nejat Dalay
- Yeşim Eralp
View Affiliations / Copyright

Affiliations: Department of Basic Oncology, Oncology Institute, Istanbul University, Istanbul 34093, Turkey, Department of Clinical Oncology, Oncology Institute, Istanbul University, Istanbul 34093, Turkey, Department of General Surgery, Istanbul Medical Faculty, Istanbul University, Istanbul 34093, Turkey
Pages: 845-848
|
Published online on: May 28, 2014

https://doi.org/10.3892/ol.2014.2188
Expand metrics +

Abstract

Previous studies have revealed the aberrant expression of a number of microRNAs (miRNA/miRs) in the blood circulation of patients with breast cancer (BC). The aim of the present study was to assess the effect of neoadjuvant chemotherapy on the levels of a panel of BC‑associated miRNAs, which are at relatively low (let‑7, miR‑10b, miR‑34, miR‑155, miR‑200c and miR‑205) or abundant (miR‑21, miR‑195 and miR‑221) levels in the circulation. Patients with primary operable or locally advanced BC were enrolled in the study. The plasma levels of the miRNAs at baseline and at the fourth cycle of treatment were compared. Patients with stage II disease exhibited higher basal miRNAs levels than those with higher stages. The difference was most evident for miR‑155 and miR‑21 (P=0.05). From the initial to the fourth cycle of chemotherapy, the miRNA levels changed substantially. In samples in which the miRNA levels generally declined, a marked decrease (≤15,500‑fold) was evident for the abundant miRNAs. Notably, the occurrence of a decrease in miRNA levels was more frequent in patients with smaller tumor sizes (P<0.05 for miR‑21 and miR‑195). This proof‑of‑concept study provides evidence that highly expressed miRNAs are affected most frequently by chemotherapy, particularly in patients with early stage tumors. This information may be valuable in assessing the response of the patients to therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000.
3	Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 100:10393–10398. 2003.
4	Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
5	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012.
6	Moulder S: Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond Engl). 6:821–830. 2010.
7	Sun Y, Wang M, Lin G, et al: Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 7:e470032012.
8	Braicu C, Calin GA and Berindan-Neagoe I: MicroRNAs and cancer therapy - from bystanders to major players. Curr Med Chem. 20:3561–3573. 2013.
9	Harquail J, Benzina S and Robichaud GA: MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark. 11:269–280. 2012.
10	Madhavan D, Cuk K, Burwinkel B and Yang R: Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 4:1162013.
11	Cuk K, Zucknick M, Heil J, et al: Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 132:1602–1612. 2013.
12	Zhao R, Wu J, Jia W, et al: Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie. 34:675–680. 2011.
13	Jung EJ, Santarpia L, Kim J, et al: Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 118:2603–2614. 2012.
14	Wang H, Tan G, Dong L, et al: Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 7:e342102012.
15	Liu H: MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci. 69:3587–3599. 2012.
16	Heneghan HM, Miller N, Kelly R, Newell J and Kerin MJ: Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 15:673–682. 2010.
17	Kumar S, Keerthana R, Pazhanimuthu A and Perumal P: Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. Indian J Biochem Biophys. 50:210–214. 2013.
18	Chen J, Wang BC and Tang JH: Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol. 106:260–266. 2012.
19	Zhao Y, Deng C, Wang J, et al: Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat. 127:69–80. 2011.
20	Sun X, Qin S, Fan C, et al: Let-7: a regulator of the ERα signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep. 29:2079–2087. 2013.
21	Zhao G, Cai C, Yang T, et al: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PloS One. 8:e539062013.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles